Small Pharma, Big Opportunity: Should CDMO Partner Size Influence Selection for your Large Molecule Project?
概述：在无菌制剂的早期开发过程中，由于资源有限和工艺开发方面的挑战，新兴生物技术公司经常难以决定选择小型还是大型 CDMO 作为其合作伙伴。这项关键决定不仅会影响早期开发，还会影响工艺放大和商业化。
Added Date:
2022-06-12Filters:
| Filter Category | Filter Values |
|---|---|
| Specialty |
|
| Capability |
|
| Language |
|
| Asset Type |
|
| Country |
|
| Region |
|
| Market Category |
|
| Content Category |
|
Country Availability:
()